ProPhase Labs, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax
ProPhase Labs, Inc. (PRPH) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax of -$7.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax · last filed 2022-11-10
- ProPhase Labs, Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2022-09-30 was -$7.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 9 month |
|---|---|---|
| 2022-09-30 | -$7.00K 10-Q · filed 2022-11-10 | -$186.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |